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A B S T R A C T  
 As important members of the innate immune response and conduits for induction of 
cell-mediated immunity, dendritic cells (DCs) have emerged as integral to understanding the 
immune response to pathogens.  Due to their role in inflammation, ability to stimulate naïve T 
cells, and widespread presence in the body, the study of their physiological response is key to 
conceptualize immune function and pathology. While dendritic cells have been shown to 
influence tolerance in T cell populations, there is a dearth of investigation as to the 
development of tolerance among DCs themselves.  In cells closely related to DCs such as 
macrophages and monocytes, prior exposure to minute amounts of endotoxin (LPS) can lead to 
a refractory period where subsequent exposure to higher doses fails to induce an inflammatory 
response. This study aims to characterize the immunomodulatory response of bone marrow-
derived dendritic cells in instances of endotoxin tolerance, as well as tolerance induced by 
bacterial sonicate containing multiple stimulatory ligands.  Murine bone marrow-derived 
dendritic cells (BM-DCs) were harvested and cultured (tolerized) with 5 ng/ml LPS or 2 µg/ml of 
either E. coli or H. pylori strain SS1 sonicate, thoroughly washed, rested, and stimulated with 
the same component at a higher dose, physiologically mimicking a low-dose primary exposure 
and a larger secondary exposure.  Along with a significant drop in TNF-α and IL-12p70 
production, tolerized BM-DCs exhibited increased IL-10 expression. Tolerization and re-
exposure to H. pylori SS1 sonicate uniquely showed a decreased expression of IL-6 in tolerized 
BM-DCs.  Furthermore, interleukin 1 receptor-associate kinase-M (IRAK-M), a negative 
regulator of TLR signaling through NF-κB, showed increased intracellular expression during 
endotoxin tolerance when its transcript was tested with qPCR and protein expression was 
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evaluated with Western blot.  Neutralization of IL-10 by a αIL-10 antibody in culture did not 
affect the expression of TNF-α in tolerized BM-DCs, indicating that suppressed pro-
inflammatory cytokine expression during tolerance is not IL-10-dependent.  Surprisingly, when 
BM-DCs were harvested from IRAK-M knockout mice, tolerance induced by LPS and bacterial 
sonicate was not prevented, and indeed the expression of TNF-α decreased.  IL-10 expression in 
IRAK-M -/- DCs increased as in wild type tolerized DCs, but this increase in IL-10 was not 
exhibited by IRAK-M -/- DCs tolerized with bacterial sonicate. IRAK-M therefore seems to play 
different roles in endotoxin tolerance (single-ligand tolerance) and bacterial sonicate tolerance 
(multi-ligand tolerance). We conclude that along with endotoxin (LPS), aggregate bacterial 
components with multiple TLR ligands are able to induce tolerance in BM-DCs, this tolerance is 
not dependent on autocrine immune suppression by IL-10, and that IRAK-M, as a negative 
regulator of TLR signaling in related cell lineages, appears to not be essential to tolerance in 
BM-DCs and may actually enhance tolerance when not expressed.  Furthermore, H. pylori SS1 
sonicate appears to decrease expression of IL-6 in tolerized BM-DCs, whereas LPS and E. coli 
sonicate do not. This indicates that global trends in endotoxin tolerance might shift depending 
on the components involved in tolerization and subsequent stimulation, and that the function 
of IRAK-M in tolerance of BM-DCs does not mirror its function in other monocytes-derived cells. 
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B A C K G R O U N D  A N D  I N T R O D U C T I O N  
 The role of dendritic cells in the innate and adaptive immune response has long been an 
area of active research.  As essential components of the immune system, they are able to 
interact innately with pathogens as well as serve as mediators to the adaptive immune 
response in their role as antigen presenting cells (APCs) [1-2].  Since they possess significant 
migratory capabilities and are able to stimulate the development of naïve T cells, DCs are 
crucial to developing antigen-specific immune responses [3-4].  Dendritic cells do not 
proliferate and have a regular course of maturation, serving as critical responders in tumor 
resistance, preventing metastasis, and combating bacterial challenge [4].  During the innate 
response, DCs secrete cytokines essential to the inflammatory response and clearance of host 
infection [3].  Upon encountering an invading pathogen, DCs are competent to ingest antigens 
via several mechanisms including phagocytosis and receptor-mediated endocytosis [5]. In 
relation to T cells, DCs are able to skew the T cell subtype proliferation in varying conditions, 
and are particularly important in regulatory T cell development [2]. Given the key role that 
dendritic cells possess as mediators of innate and adaptive immune response, special attention 
has also been given to them as targets of vaccine development by serving as a vaccine vector 
[4, 6-9]. DCs, as a leukocyte group, are fairly heterogeneous and have complex physiological 
function, thus underscoring the need for a better understanding of their function. 
 Despite the knowledge gathered on their role in adaptive tolerance, there is 
comparatively little known about tolerization of dendritic cells themselves.  In monocytes and 
macrophages, which are closely related in function to dendritic cells, cellular tolerance has been 
shown to occur in septic patients and with various TLR ligands, particularly the pyrogenic 
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endotoxin (lipopolysaccharide, or LPS) derived from Gram (-) bacteria [10-14].  Monocytes, 
macrophages, and dendritic cells all respond to bacterial components such as endotoxin 
through what have been termed pattern recognition receptors (PRRs) expressed on the surface 
of their cells [1, 13, 15-17].  Toll-like receptors (TLRs), necessary for the recognition of 
endotoxin and a wide array of pathogen-associated molecular patterns (PAMPs), are the major 
PPRs involved in cytokine response and co-stimulatory molecule expression when monocyte-
derived cells are exposed to bacterial infection [13]. Extracellular and endosomal signaling by 
PAMPs through TLRs leads to cytokine activation through NF-κB and MAP kinase pathways, and 
this signaling is essential to inflammation and eventual activation of the adaptive immune 
response [1].   Immune response and inflammation is a complex pathophysiological state, and 
the investigation of endotoxin tolerance (ET) stems from the first descriptions of endotoxin 
tolerance in patients in the mid-20th century where re-exposure to endotoxin after an initial 
exposure to minute levels failed to induce fever as it typically does on initial exposure [18-24]. 
This hyporesponsiveness to otherwise stimulatory bacterial components would suggest the 
development of intracellular regulation of TLR signaling within the cells that detect bacterial 
components and release inflammatory signals.  
 Indeed, regulation of the inflammatory response through adaptive mechanisms is an 
important means to check autoimmune reactions and cancer, maintain normal metabolic 
function, and prevent the emergence of over-compensatory immune reaction in the form of a 
tissue-damaging “cytokine storm” [5, 16, 22, 25-28].  This type of immune regulation would be 
predicted to serve an important role in a septic infection; development of endotoxin shock 
during sepsis is avoided if the host develops endotoxin tolerance, or a refractory period after 
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exposure to minute amounts of endotoxin [18, 20, 22-23, 29-31]. This phenomenon where cells 
exposed to low concentrations of LPS shift into transient unresponsiveness to further 
stimulation with LPS would, therefore, seem evolutionarily favorable to survival. However, a 
delicate balance must be achieved to keep the immune system under control while not 
suppressing its function so severely as to prevent it from being able to clear the pathogen or 
combat secondary infections. 
 This phenomenon has been shown to occur in vivo and in vitro in human and animal 
models, with essentially all in vitro experiments dealing with monocytes and macrophages [10-
11, 14, 23, 32-35].  It was shown that hyporesponsiveness of circulating human monocytes 
could be induced with as little as one hour of exposure to low-dose LPS, and that this tolerant 
state was maintained for up to 5 days, after which the cells reverted to a phenotype similar to 
that exhibited pre-exposure [11]. This tolerant phenotype is correlated with the up-regulation 
of a number of cell receptors, enhanced phagocytosis, decreased antigen presentation, and a 
decrease in pro-inflammatory cytokine release [19, 21, 25, 35-36].   ET has been identified as 
playing a role in diverse pathological settings besides sepsis, including trauma, surgery, 
pancreatitis, hepatic ischemia, acute coronary syndrome, cystic fibrosis, and even cancer [5, 13, 
15, 22, 24, 29, 37].  However, the behavior of dendritic cells during this sort of transient 
unresponsiveness, as well as how dendritic cells respond to aggregated bacterial components, 
has been left mostly unexplored. 
 Further investigation into endotoxin tolerance seems to suggest not just a simple 
instance of immunosuppression of monocytes and macrophages during transient tolerance, 
since pro-inflammatory cytokines (such as TNF-α and IL-12) tend to decrease their expression, 
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whereas as anti-inflammatory cytokines (such as IL-10 and TGF-β) tend to increase their 
expression. Thus, it has been suggested to describe ET as an instance of “immunomodulation” 
to better encapsulate the altered, rather than decreased, function of the immune cells [13].  
Even though inflammatory cytokines activated by NF-κB and anti-inflammatory cytokines (such 
as IL-10) are both activated through TLR4 signaling by LPS, they are controlled by different 
adaptor molecules (MyD88 vs TRIF), and thus their pathways can be differentially regulated 
[38]. Besides modification of signaling pathways, it has been further demonstrated that ET 
leads to histone modification within chromatin, which modifies the accessibility of transcription 
factors and RNA polymerase to genes [39].  Exposure to LPS was shown to lead to histone 
modification in tolerant and non-tolerant cells, however only in tolerant cells were particular 
antimicrobial genes activated for transcription, indicating the first LPS exposure as a “warm-up” 
for the second exposure during which a more robust response of antimicrobial genes 
developed [16, 26]. 
A key immunomodulatory molecule that has arisen as important in endotoxin tolerance 
is interleukin-1 receptor-associated kinase-M (IRAK-M). In human circulating monocytes of 
human septic patients that display refractory tolerance, IRAK-M is expressed in much higher 
levels, and it has been shown to be essential for ET in vitro in macrophages [12, 14, 34, 40]. 
IRAK-M has been identified as a potent negative regulator of TLR signaling through MyD88 
leading to decreased signaling through NF-κB and consequently decreased expression of the 
pro-inflammatory cytokines for which it serves as a transcriptional activator (TNFA, IL1B, IL6, 
and IL12B, among others) [40].  It is unclear how exactly IRAK-M functions, but current models 
describe IRAK-M as inhibiting the separation of IRAK-1 and IRAK-4 from the TLR signaling 
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complex. This prevents further signaling in the cascade to deactivation of IκB, which allows NF-
κB activation, by either stabilizing the TLR/MyD88/IRAK-1/4 complex or inhibiting 
phosphorylation of IRAK-1 and IRAK-4 [40].  It has been observed in murine macrophages and 
human monocytes that the ET state correlates with impaired IRAK-1 activity [28, 31], so it is not 
unusual that IRAK-M might play an important role in maintaining ET in these cells.  It has been 
demonstrated that IRAK-M is up-regulated in macrophages and monocytes, and a few groups 
have shown it as “essential” for transient tolerance in these cells [10, 38, 40].  In dendritic cells, 
IRAK-M has not been characterized or shown to be present, nor has it been shown what role, if 




H Y P O T H E S I S  
Based on the inflammatory response of human and murine monocytes and 
macrophages during endotoxin tolerance, and a few studies that have indicated tolerance in 
dendritic cells, we hypothesize the following: 
 When murine BM-DCs are tolerized with low levels of LPS or bacterial sonicate and then 
re-exposed to the same component, they will exhibit cytokine modulation compared to 
an untolerized control 
o Decreased levels of pro-inflammatory cytokine production (TNF-α, IL-6, IL-12) 
o Increased levels of anti-inflammatory cytokine production (IL-10) 
 During endotoxin tolerance and bacterial sonicate tolerance, autocrine function of IL-10 
will contribute to the decreased expression of pro-inflammatory cytokines 
 During endotoxin tolerance, interleukin 1 receptor-associated kinase-M (IRAK-M), a 
negative regulator of TLR signaling, will be expressed in increased amounts over an 
untolerized control 
 Tolerance with LPS or bacterial sonicate will be ablated in IRAK-M knockout mice due to 
the role of IRAK-M in negatively regulating inflammatory TLR signaling  
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M A T E R I A L S  A N D  M E T H O D S  
Mice  
Specific-pathogen-free C57BL/6 mice aged 8–10 weeks were purchased from Jackson 
Laboratory (Bar Harbor, ME) and housed in the animal maintenance facility at the University of 
Michigan Health System under SPF conditions..  Experiments were conducted on mice between 
the ages of 10 and 14 weeks.  IRAK-M -/- mice with a truncated functional domain were 
generously provided Ted Standiford (University of Michigan Medical School, Department of 
Internal Medicine, Pulmonary and Critical Care Medicine), and were the same age as wild type 
mouse when chosen for experimentation.  All animal experiments were approved by the 
University of Michigan Animal Care and Use Committee. 
 
Media and cytokines 
For all experiments, bone marrow-derived DCs were cultured in complete medium 
consisting of RPMI-1640 (Sigma) with 9% heat-inactivated fetal calf serum (ISC Biosciences), 2 
mM  added glutamine (4 mM total), 100 U/ml penicillin, and 100 µg/ml streptomycin. The 
following recombinant cytokines (R&D Systems, Minneapolis, MN) were diluted in complete 
medium during culturing: mouse granulocyte/macrophage colony-stimulating factor (GM-CSF; 
10 ng/ml) and mouse IL-4 (10 ng/ml).  After harvest of the cells at day 6 for experimentation, 






Bacterial strains and culture conditions  
Helicobacter pylori was grown on Campylobacter-selective agar (BD Diagnostics, 
Bedford, MA) and supplemented with 5% sterile horse blood, trimethoprim (5 µg/ml), 
vancomycin (10 µg/ml), and nystatin (10µg/ml) for 2-4 days at 37°C in a humidified 
microaerophilic chamber (BBL Gas System, with CampyPak Plus packs, BD Microbiology, Sparks, 
MD). In vitro experiments were performed using H. pylori SS1 which was grown as described 
above. E. coli was cultured overnight in Luria-Bertani (LB) medium at 37°C.  To prepare the 
bacterial sonicate, bacteria were diluted in PBS (Invitrogen) to a concentration of 1 x 109 /ml 
and subjected to repeated sonication in an ultrasonic bath to produce a crude bacterial 
sonicate.  Protein levels were assayed using a BSA standard (Bio-Rad), and protein 
concentration was used as representative of proportional amounts of all bacterial components. 
LPS was purchased from Sigma and was derived from E. coli strain O127:B8. LPS was diluted in 
PBS. 
 
Generation of bone marrow-derived DCs.  
Mice were humanely euthanized with CO2 and the femur and tibia were promptly 
excised for extraction of bone marrow.  Muscles and tendons were removed from the femur 
and tibia by gentle scraping with a blade until clean and washed with ethanol.  The epiphyses of 
the bones were removed to expose the marrow. Murine bone marrow cells were suspended in 
PBS, treated with an ionic lysing buffer in order to deplete red blood cells, and cultured in 
complete medium with 10 ng/ml GM-CSF and 10 ng/ml IL-4 at 1 x 106 cells/ml. On day 3, 50% of 
the complete media was aspirated and replaced. On day 6, non-adherent DCs were harvested 
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by vigorous pipetting and enriched by gradient centrifugation using the OptiPrep density 
solution (Sigma) according to manufacturer’s instruction. The interface between the high and 
low density solutions containing the DCs was collected by gentle aspiration. The recovered DCs 
were washed twice with RPMI-1640 and cultured in complete medium with GM-CSF (10 ng/ml). 
 
Tolerization and stimulation of DCs 
 DCs were tolerized with either 10 ng/ml LPS (unless otherwise indicated) or 2 µg/ml 
sonicate from Escherichia coli or Helicobacter pylori produced as described above. Cells were 
allowed to tolerize for 7-8 hours. After tolerization, culture media was collected and cells were 
washed 3 times with PBS (Invitrogen).  Cells were then re-plated with complete media and 
allowed to rest overnight (16-18 hrs). This rest period was altered only for the initial dose 
response and time course experiments, where the rest period was around an hour. A second 
stimulation was then administered of 100 ng/ml LPS (unless otherwise noted) or 10 µg/ml 
bacterial sonicate from Escherichia coli or Helicobacter pylori produced as described above.  




 DCs were collected at three hours by media aspiration and cell scraping.  Cells were 
promptly centrifuged, media aspirated, and treated with TRIzol reagent per instructions of 
manufacturer (Invitrogen).  mRNA pellets were reconstituted in nuclease-free water and purity 
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analysis was done.  All samples used for analysis had A260/A280 ratios greater than 1.9 upon 
spectrophotometric analysis. 
 
cDNA synthesis and qPCR 
 Total mRNA isolated from TRIzol extraction was adjusted to a concentration of 250 
µg/ml and 1 µg of sample was used to synthesize cDNA using iScript cDNA synthesis kit in 20 µl 
solutions per instructions of manufacturer (Bio-Rad).  cDNA was then analyzed by qPCR using iQ 
SYBR Green Supermix per instructions of manufacturer (Bio-Rad).  GAPDH was used as an 
endogenous housekeeping reference gene. Murine primers (Invitrogen) were: 
 GAPDH – Forward: 5’ – TCAAGAAGGTGGTGAAGCAGG - 3’ reverse: 5’ –
TATTATGGGGGTCTGGGATGG - 3’ 
 IL-10 – Forward: 5’ - CTTACTGACTGGCATGAGGATCA - 3’ reverse: 5’- 
AGCTGGTCCTTTGTTTGAAAGAAA – 3’ 
 IRAK-M – Forward: 5’ – TGAGCAACGGGACGCTTT – 3’ reverse: 5’ – 
GATTCGAACGTGCCAGGAA – 3’ 
 
ELISA analysis 
 Supernatant was collected and centrifuged at 8 hours post second stimulation, and cell-
free supernatants were stored in -200 for analysis.  TNF-α, IL-6, IL-10, and IL-12p70 cytokine 







 DCs were collected through aspiration and plate scraping, centrifuged, washed once 
with PBS, and lysed with solution containing protease and phosphatase inhibitors (Cell Signaling 
Technologies) to release intracellular protein. Protein levels were then equilibrated and run 
through SDS-PAGE. Proteins were then transferred onto PVDF membrane, blotted with primary 
and secondary antibodies (Abcam), and protein detection was carried out by 
chemiluminescence. GAPDH was used as an endogenous housekeeping reference protein.  
 
IL-10 neutralization 
IL-10 neutralization was performed with purified recombinant goat IgG antibody specific 
for murine IL-10 (R&D Systems).  Antibody was tested to be preservative-, and carrier-free.  
Neutralizing antibody was diluted in sterile PBS and frozen at -20o, and working concentration 
in cell culturing conditions was 800 ng/ml, a concentration shown by manufacturer IL-10 
neutralization data to exhibit >85% neutralization of IL-10 at concentrations below 2.5 ng/ml of 
IL-10.  ND50 is 30-100 ng/ml according to manufacturer data.
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R E S U L T S  
The results of the current study reveal a number of novel findings related to tolerance 
within bone marrow-derived dendritic cells. 
 
BM-DCs tolerized with endotoxin and bacterial sonicate exhibit decreased expression of pro-
inflammatory cytokines TNF-α and IL-12p70 
 Bone marrow-derived dendritic cells were cultured for 6 days in complete media 
supplemented with FBS, GM-CSF, and IL-4 and enriched by density gradient centrifugation.   As 
might be expected in tolerized dendritic cells, levels of the pro-inflammatory cytokines TNF-α 
and IL-12p70 were significantly decreased when cells were first treated with low dose LPS (10 
ng/ml), H. pylori strain SS1 sonicate (2 µg/ml), and E. coli sonicate (2 µg/ml) for 8 hours, washed 
thoroughly, allowed to rest overnight, and then subsequently stimulated with the same 
component they were tolerized with but at higher doses, either LPS (100 ng/ml), SS1 sonicate 
(10 µg/ml), or E. coli sonicate (10 µg/ml) (Figure 3 and Figure 4).  Along with demonstrating an 
adequate model of dendritic cell tolerization with respect to these pro-inflammatory cytokines, 
this is the first demonstration of dendritic cell tolerization with crude bacterial sonicate. These 
results indicate that dendritic cells may not only be tolerized with a single TLR ligand (LPS), but 
also by a crude bacteria extract containing numerous TLR ligands and other PAMPs, and that 
these additional PAMPs do not prevent the development of tolerance with respect to the 
inflammatory cytokines TNF-α and IL-12p70.  Tolerance occurred to nearly the same degree 
regardless of whether the bacterial sonicate was derived from Helicobacter pylori strain SS1 or 
Escherichia coli.  
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BM-DCs tolerized with endotoxin and bacterial sonicate exhibit increased expression of the anti-
inflammatory cytokine IL-10 
 As has been shown to occur in macrophages and monocytes, the potent anti-
inflammatory cytokine IL-10 was expressed in significantly elevated levels when cells were first 
treated with low dose LPS (10 ng/ml), H. pylori strain SS1 sonicate (2 µg/ml), and E. coli sonicate 
(2 µg/ml) for 8 hours, washed thoroughly, allowed to rest overnight, and then subsequently 
stimulated with the same component they were tolerized with but at higher doses, either LPS 
(100 ng/ml), SS1 sonicate (10 µg/ml), or E. coli sonicate (10 µg/ml) (Figure 5 and Figure 6).  This 
was shown preliminarily though measurement of IL-10 transcript (Figure 5) as well as directly 
measured protein levels (Figure 6). Although IL-10 release has been shown to be increased in 
LPS-tolerized DCs, increased IL-10 expression in cells tolerized and subsequently stimulated 
with crude bacterial sonicate represents a novel finding.  In keeping with the observed 
tolerogenic phenotype of sonicate-tolerized dendritic cells with regards to TNF-α and IL-12p70, 
these tolerized cells express IL-10 in increased amounts with both single ligand stimulation and 
multiple ligand stimulation from bacterial sonicate.  The degree of increased IL-10 expression 
did not appear to vary significantly between sonicate derived from H. pylori or E. coli.  This 
trend in IL-10 expression of tolerized DCs further supports the tolerance model of the current 
experiment. 
 
BM-DCs tolerized with H. pylori SS1 sonicate, but not endotoxin or E. coli sonicate, exhibit 
decreased expression of the pro-inflammatory cytokine IL-6 
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 Expression of IL-6 in LPS- and sonicate-tolerized BM-DCs shows a deviation from the 
relatively uniform trends in expression of TNF-α, IL-12p70, and IL-10.  The pro-inflammatory 
cytokine was not expressed in significantly elevated levels when cells were first treated with 
low dose LPS (10 ng/ml) or E. coli sonicate (2 µg/ml) for 8 hours, washed thoroughly, allowed to 
rest overnight, and then subsequently stimulated with the same component they were 
tolerized with but at higher doses, either LPS (100 ng/ml) E. coli sonicate (10 µg/ml) (Figure 7), 
as might be predicted from the trend in TNF-α and IL-12p70 in tolerized DCs.  However, in DCs 
tolerized with H. pylori SS1 sonicate, IL-6 expression is decreased with relation to non-tolerized 
DCs.  IL-6, IL-12p70, and TNF-α transcription are all influenced by signaling through NF-κB, so 
this trend in IL-6 expression in LPS- and E. coli sonicate-tolerized DCs is interpreted as unusual.    
This indicates that Helicobacter pylori crude sonicate may possess a component that is able to 
uniquely influence IL-6 expression whereas as LPS and E. coli sonicate do not. 
 
Autocrine action of IL-10 does not contribute to suppressed TNF-α expression in BM-DCs 
tolerance with endotoxin or H. pylori SS1 sonicate 
 To examine the influence of IL-10 in the development of tolerance in bone marrow 
derived dendritic cells, cells were tolerized and subsequently stimulated in the presence of an 
IL-10 neutralizing antibody.  Tolerization was conducted with LPS and H. pylori sonicate and 
followed the same procedure as previously described.  After 8 hours of stimulation, IL-10 was 
assayed for by ELISA and revealed undetectable levels (data not shown).  In dendritic cells 
tolerized with LPS and H. pylori SS1 sonicate, there was no significant alteration in the 
development of tolerance when IL-10 was neutralized (Figure 8).   This indicates that IL-10 does 
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not act in an autocrine fashion to suppress the expression of the pro-inflammatory cytokine 
TNF-α.  IL-10 has been shown to suppress TNF-α expression, however it appears that TNF-α is 
suppressed in tolerant dendritic cells through mechanisms independent of IL-10.  
 
BM-DCs tolerized with endotoxin display increased expression of IRAK-M transcript and protein 
 In order to determine if IRAK-M, a negative regulator of TLR signaling, demonstrated 
increased expression when BM-DCs were tolerized with low dose LPS (10 ng/ml) and then re-
exposed to a higher LPS dose (100 ng/ml), cells were assayed for the presence of IRAK-M 
transcript and protein.  This protein was shown to be up-regulated in macrophages and 
monocytes when these cells are tolerized, and has even been shown to be “essential” to 
tolerance, but has not been identified or characterized in dendritic cells.  Our results indicate 
significantly increased expression of IRAK-M transcript in tolerized BM-DCs as determined by 
qPCR, as well as an increase in IRAK-M protein expression as determined by Western blot 
(Figure 9).  Since, in the literature, IRAK-M has not been confirmed to be present in dendritic 
cells, this represents a novel identification.  Given the similar increase in IRAK-M during 
tolerance as in macrophages and monocytes, these results point to the possibility of IRAK-M 
having an analogous role in tolerance in dendritic cells 
 
IRAK-M is not essential to tolerance in BM-DCs with respect to TNF-α, but does affect IL-10 
expression in BM-DCs tolerized with bacterial sonicate 
 Utilizing BM-DCs derived from IRAK-M knockout (truncated functional domain) mice, 
the absence of IRAK-M was shown to not affect the development of tolerance with respect to 
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TNF-α in BM-DCs tolerized with low dose LPS (10 ng/ml), H. pylori strain SS1 sonicate (2 µg/ml), 
or E. coli sonicate (2 µg/ml) for 8 hours, washed thoroughly, allowed to rest overnight, and then 
subsequently stimulated with the same component they were tolerized with but at higher 
doses, either LPS (100 ng/ml), SS1 sonicate (10 µg/ml), or E. coli sonicate (10 µg/ml) (Figure 10 
and Figure 11).  In fact, in wild type BM-DCs compared to IRAK-M -/- BM-DCs, tolerized IRAK-M 
-/- cells showed a significant decrease in the expression of TNF-α.  This is a peculiar finding in 
light of the role of IRAK-M as a negative regulator of TLR signaling; if IRAK-M acts as a negative 
regulator of inflammatory signaling, removing the expression of the protein in the cells should 
result in the recovery of pro-inflammatory cytokine response in tolerized BM-DCs, yet this was 
not observed.  Indeed, the opposite effect was observed in the absence of expression of IRAK-
M.  IRAK-M -/- BM-DCs also maintained the tendency to increase IL-10 expression in only 
endotoxin-tolerized cells; however this ability was not maintained in IRAK-M -/- cells tolerized 
with H. pylori SS1 sonicate or E. coli sonicate and subsequently re-stimulated with a higher 
amount of sonicate (Figure 11), as was demonstrated in wild type BM-DCs.  These sonicate-
tolerized cells showed no significant difference in IL-10 expression regardless of tolerization 
status.  This indicates that IRAK-M may play differing roles as a negative regulator of TLR 
signaling in cells tolerized with a single stimulatory ligand, such as with LPS alone, or multiple 
stimulatory ligands, such as with crude bacterial sonicate.  Other regulators may also play a 
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F I G U R E  1 .   TNF-α expression with varying low doses of LPS tolerization and 
subsequent higher dose stimulation. 8 hrs after second stimulation (n=3).  Dendritic 
cells were tolerized with either no LPS, 5 ng/ml LPS, or 10 ng/ml LPS overnight, 
thoroughly washed, rested for a short period (less than an hour), and re-stimulated with 
the indicated dose of LPS (x-axis) to physiologically mimic primary and secondary 
exposures. Tolerance with 10 ng/ml LPS and stimulation with 100 ng/ml LPS was 
continued throughout the current study.  Note: procedure was modified in later 
experiments since rest time was deemed to be of inadequate length to allow cells to 
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F I G U R E  2 .   TNF-α expression by BM-DCs during tolerance time course. Cell-free 
supernatant harvested at 1-8 hrs after second stimulation (n=3).  Dendritic cells were 
tolerized with 10 ng/ml LPS, thoroughly washed, rested for a short period (less than an 
hour), and re-stimulated with 100 ng/ml LPS to physiologically mimic primary and 
secondary exposures. Tolerance with 10 ng/ml LPS and stimulation with 100 ng/ml LPS 
was continued throughout the current study.  Note: procedure was modified in later 
experiments since rest time was deemed to be of inadequate length to allow cells to 




TNF-  in DCs tolerized with LPS

















TNF-  in DCs tolerized with SS1 sonicate


















TNF-  in DCs tolerized with E. coli sonicate


















F I G U R E  3 . TNF-α expression decreases in supernatant of DCs tolerized with LPS, H. 
pylori SS1 sonicate, or E. coli sonicate. 8 hrs after 2nd stimulation (n=3).  A-C, Tolerized DCs 
exhibit a significant ablation in secreted TNF-α (a potent pro-inflammatory cytokine) upon 
second stimulation by higher dose LPS, SS1 sonicate, or E. coli sonicate. Non-tolerized DCs 
display a robust TNF- α response upon stimulation with higher dose LPS, SS1 sonicate, or E. 
coli sonicate. This confirms that, with respect to TNF-α cytokine expression, BM-DCs behave 
in a similar manner as monocytes and macrophages under conditions of tolerance due to 
previous exposure to low-dose stimulation with LPS.  A similar effect is observed with 
tolerance due to low dose bacterial sonicate exposure. 1st/2nd dose LPS = 10/100 ng/ml.  







IL-12p70 in DCs tolerized with LPS


















IL-12p70 in DCs tolerized with SS1 sonicate





















IL-12p70 in DCs tolerized with E. coli sonicate
























F I G U R E  4 . IL-12p70 expression decreases in supernatant of DCs tolerized with LPS, E. 
coli sonicate, or H. pylori SS1 sonicate. 8 hrs after 2nd stimulation (n=3).  A-C, Tolerized DCs 
exhibit a significant decrease in secreted IL-12p70 (a potent pro-inflammatory cytokine) 
upon second stimulation by higher dose LPS, SS1 sonicate, or E. coli sonicate. Non-tolerized 
DCs display a robust IL-12p70 response upon stimulation with higher dose LPS, SS1 sonicate, 
or E. coli sonicate. This confirms that, with respect to IL-12p70 cytokine expression, BM-DCs 
behave in a similar manner as monocytes and macrophages under conditions of tolerance 
due to previous exposure to low-dose stimulation with LPS.  A similar effect is observed with 
tolerance due to low dose bacterial sonicate exposure.  1st/2nd dose LPS = 10/100 ng/ml.  





[IL-10/GAPDH] in DCs with LPS tolerance, 3 hrs. after 2nd stimulation





















[IL-10/GAPDH] in DCs with SS1 sonicate tolerance, 3 hrs. after 2nd stimulation























F I G U R E  5 . IL-10 mRNA and secreted protein expression in DCs tolerized with LPS or H. 
pylori SS1 sonicate.  A-B, 3 hrs after 2nd stimulation (n=1).  Preliminary experiment to 
determine IL-10 (a potent anti-inflammatory cytokine) behavior during tolerance.  In both 
the LPS and SS1 tolerized groups, there is increased production of IL-10 transcript upon 
second stimulation by a higher dose of LPS or SS1 sonicate. Data normalized to GAPDH 
endogenous housekeeping reference gene. 1st/2nd dose LPS = 10/100 ng/ml.  1st/2nd dose 




IL-10 in DCs tolerized with LPS

















IL-10 in DCs tolerized with SS1 sonicate

















IL-10 in DCs tolerized with E. coli sonicate





















F I G U R E  6 .  IL-10 secreted protein expression in DCs tolerized with LPS, H. pylori SS1 
sonicate, or E. coli sonicate.  A-C, BM-DC supernatant 8 hrs after 2nd stimulation (n=3).  
Closely tracking the mRNA results, tolerized DCs show a significant increase in secreted IL-10 
(a potent anti-inflammatory cytokine) upon second stimulation by higher dose LPS, SS1 
sonicate, or E. coli sonicate. Non-tolerized DCs display less IL-10 expression upon stimulation 
with higher dose LPS, SS1 sonicate, or E. coli sonicate. 1st/2nd dose LPS = 10/100 ng/ml.  





IL-6 in DCs tolerized with LPS














IL-6 in DCs tolerized with SS1 sonicate
















IL-6 in DCs tolerized with E. coli sonicate


















F I G U R E  7 . IL-6 expression in supernatant of DCs tolerized with LPS, H. pylori SS1 
sonicate, or E. coli sonicate. 8 hrs after 2nd stimulation (n=3).  A,C, Tolerized DCs exhibit no 
significant modulation of secreted IL-6 (a potent pro-inflammatory cytokine) upon second 
stimulation by higher dose LPS or E. coli sonicate as compared with non-tolerized DCs, 
which display a similar IL-6 response upon stimulation with higher dose LPS or E. coli 
sonicate.  B, However, IL-6 expression by DCs tolerized with SS1 sonicate showed 
significantly decreased levels of IL-6 expression as compared to non-tolerized DCs, which 
show a robust IL-6 response to SS1 sonicate stimulation. 1st/2nd dose LPS = 10/100 ng/ml.  
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F I G U R E  8 . TNF-α expression in supernatant of DCs tolerized with LPS and H. 
pylori SS1 sonicate with or without IL-10 neutralizing antibody.  8 hrs after 2nd 
stimulation (n=3).  A-B, Tolerized DCs exhibit a significant ablation in secreted TNF-α (a 
potent pro-inflammatory cytokine) upon second stimulation by higher dose LPS or SS1 
sonicate regardless of whether IL-10 was neutralized by an antibody.  IL-10 
neutralization was confirmed by ELISA and IL-10 was undetectable (data not shown). 
This demonstrates that IL-10 does not appear to have an autocrine role in suppressing 
TNF-α expression in tolerized BM-DCs. 1st/2nd dose LPS = 10/100 ng/ml.  1st/2nd dose 





[IRAK-M/GAPDH] in DCs tolerized with LPS, 3 hrs. after 2nd stimulation


























F I G U R E  9 . IRAK-M mRNA and protein expression in DCs tolerized with LPS.  A, qPCR 
3 hrs after 2nd stimulation (n=3).  IRAK-M is a negative regulator of TLR signaling and has 
been shown to be essential to endotoxin tolerance in other monocyte-derived cell 
lineages. With LPS tolerance there is an observably increased production of IRAK-M 
transcript upon second stimulation by a higher dose of LPS. Data normalized to GAPDH 
endogenous housekeeping reference gene. B, Western blot 8 hrs after 2nd stimulation. BM-
DCs tolerized with low-dose LPS and re-exposed to high-dose LPS appear to show 
increased intracellular IRAK-M expression compared to untolerized cells.  1st/2nd dose LPS 





TNF-  in DCs tolerized with LPS, wild type vs. IRAK-M -/- mice




















TNF-  in DCs tolerized with SS1 sonicate, wild type vs. IRAK-M -/- mice




















TNF-  in DCs tolerized with E. coli sonicate, wild type vs. IRAK-M -/- mice
























F I G U R E  1 0 . TNF-α expression in supernatant of wild type vs IRAK-M -/- DCs tolerized with 
LPS, H. pylori SS1 sonicate, or E. coli sonicate.  8 hrs after 2nd stimulation (n=3).  A-C, Tolerized DCs 
exhibit a significant ablation in secreted TNF-α (a potent pro-inflammatory cytokine) upon second 
stimulation by higher dose LPS, SS1 sonicate, or E. coli sonicate, regardless of whether cells were 
derived from IRAK-M -/- or wild type mice.  Furthermore, IRAK-M -/- mice showed a greater degree 
of tolerance than wild type mice in relation to TNF-α release.  1st/2nd dose LPS = 10/100 ng/ml.  




IL-10 in DCs tolerized with LPS, wild type vs. IRAK-M -/- mice




















IL-10 in DCs tolerized with SS1 sonicate, wild type vs. IRAK-M -/- mice


















IL-10 in DCs tolerized with E. coli sonicate, wild type vs. IRAK-M -/- mice




















F I G U R E  1 1 . IL-10 expression in supernatant of wild type vs IRAK-M -/- DCs tolerized with LPS, H. 
pylori SS1 sonicate, or E. coli sonicate.  8 hrs after 2nd stimulation (n=3).  A, LPS tolerized BM-DCs 
exhibit increased levels of IL-10 upon second stimulation by higher dose LPS regardless of whether cells 
were derived from IRAK-M -/- or wild type mice.  B-C, SS1 sonicate and E. coli sonicate tolerized BM-
DCs show little modulation of IL-10 in IRAK-M -/- BM-DCs as compared to wild type BM-DCs. This 
indicates a different influence of IRAK-M in BM-DCs tolerized with a single ligand (LPS) or multiple 
ligands (sonicate) with relation to IL-10 expression.  1st/2nd dose LPS = 10/100 ng/ml.  1st/2nd dose 




D I S C U S S I O N  
Although tolerance within monocytes and macrophages has been extensively explored, 
tolerance within dendritic cells remains investigated to a far lesser degree.  Recent studies in 
dendritic cell tolerance have demonstrated the behavior of tolerized dendritic cells to individual 
ligands, as well as the changes in cell surface marker phenotype [17, 41-43].  Yet, more detailed 
study of regulation during tolerance in dendritic cells, as well as dendritic cells tolerance in the 
context of multiple ligands, was needed.  This study aimed to develop a model of endotoxin 
tolerance within murine bone marrow-derived dendritic cells (BM-DCs), observe tolerance with 
crude bacterial components, as well as investigate the role of IL-10 (a potent anti-inflammatory 
cytokine) and IRAK-M in DC tolerance.  IRAK-M was identified as essential to endotoxin 
tolerance in macrophages and monocytes, yet remained unidentified and uncharacterized in 
dendritic cells.  Overall, the role of dendritic cells in adaptive tolerance has been well-
investigated [3, 44], but a scarcity of research remains surrounding how DCs themselves might 
be tolerized. 
After first exploring endotoxin dose response and time-dependent expression of TNF-α 
in BM-DCs tolerized with low dose endotoxin (Figure 1 and Figure 2), a model was established 
with an initial low dose tolerization of 10 ng/ml LPS, a thorough wash, and a subsequent 
stimulation with 100 ng/ml LPS.  Although not performed in dose response and time course 
experiments, an overnight rest was added to allow the cells to adequately recover.  Permitting 
recovery time was deemed prudent after an extensive examination of tolerization in the 
literature.  This model of a low dose followed by a higher dose has been used in several studies 
to imitate what would, in vivo, be primary and secondary exposures [13].  Along with LPS, crude 
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bacterial sonicate derived from Helicobacter pylori strain SS1 and Escherichia coli was used to 
tolerize BM-DCs, of which the tolerization dose (2 µg/ml) and stimulation dose (10 µg/ml) were 
determined in a similar fashion (data not shown, units of measure are µg/ml protein, taken as 
representative of proportional amounts of bacterial components).  A model of tolerance with 
bacterial sonicate was developed in order to determine how dendritic cells might behave when 
exposed to multiple stimulatory ligands, TLR or otherwise, since this multi-ligand tolerance has 
not been investigated.  Understanding how dendritic cells respond to tolerizing stimuli with 
crude bacterial sonicate, and whether or not they are able to be tolerized with sonicate, might 
be more representative of in vivo conditions than single-ligand tolerance (such as with only LPS) 
since bacterial components are typically present within the environment in which dendritic cells 
function.  Bacteria and their components are regularly ingested or otherwise inoculated into 
essentially all organisms, so a model of initial and secondary exposure could mimic repeated 
exposure in the stomach or bowel, shown to be sites of DC function, or of circulating dendritic 
cells in a systemic infection. How dendritic cells respond to initial stimuli is critical to how they 
interact later in modeling the adaptive immune response [45].  E. coli was taken as an 
archetypal model of Gram (-) bacterial exposure, and H. pylori was chosen due to its interesting 
immunomodulatory capabilities and its ability to chronically colonize the gastric epithelium, 
recently shown to be a site where the bacterium and dendritic cells interact (Kao, awaiting 
publication). Additionally, H. pylori has been shown to demonstrate complex pathologies 
involving, but not limited to, gastric cancer, esophageal cancer, asthma, gastroesophageal 
reflux disease, and inflammatory bowel disease [46-51]. 
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Examination of the literature revealed that monocyte-derived cells, such as mature 
monocytes, macrophages, and to a lesser extent dendritic cells, can be tolerized and display a 
typical modulated cytokine response, with significantly decreased pro-inflammatory cytokine 
response (TNF-α, IL-12, IL-6, IL-1β) and increased anti-inflammatory cytokine response (IL-10, 
TGF-β) [5, 10-13, 17, 23, 28, 30-31, 34, 37, 39, 42-43, 52-59].  Furthermore, these cells display a 
regular pattern of decreased antigen presentation, enhanced phagocytosis, and expression of 
negative regulators (particularly IRAK-M) [19, 21, 25, 35-36]. This type of tolerance has been 
implicated in a wide array of acute and chronic diseases, ranging from sepsis to cystic fibrosis 
[13].  In addition to LPS derived from the two bacteria used in this study (Helicobacter pylori 
and Escherichia coli), the sonicate would also include various cell wall components, flagellin, 
intracellular proteins, genetic material in the form of RNA and DNA, and lipoproteins, all of 
which can lead to inflammatory signaling via TLR and other receptors, as well as endocytosis 
[1].   Although LPS is considered the major source of inflammation through TLR4 signaling, other 
components that signal through TLR receptors (lipoproteins, TLR1-6; CpG DNA, TLR9; flagellin, 
TLR 5; RNA, TLR7-8) are highly capable of potentiating inflammatory responses individually [1].  
There are also varying signaling cascades/pathways and adaptor molecules through which the 
TLR stimulation may flow [1], as well as negative regulators of this signaling [38], thus making 
the question of whether tolerance can occur in DCs with various stimulatory components an 
interesting one to investigate.  
The current study has demonstrated that, in addition to macrophages and monocytes, 
BM-DCs possess the ability to become tolerized, and that this tolerance can occur not just with 
endotoxin but also bacterial sonicate with an aggregate of microbial components.  With respect 
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to the inflammatory cytokines TNF-α and IL-12p70, tolerized DCs showed significantly 
decreased expression (Figure 3 and Figure 4).  Interestingly, though, the inflammatory cytokine 
IL-6 only showed a significant decrease during tolerization when the tolerization occurred with 
H. pylori sonicate (Figure 7). This effect is intriguing since IL-6, IL-12, and TNF-α are all under the 
regulation of NF-κB, and the fact that IL-6 is differentially regulated by H. pylori sonicate 
tolerization may indicate the presence of an H. pylori-derived factor that is able to drive the 
suppression or IL-6 specifically.  It has been shown that H. pylori-derived components can 
inhibit IL-12 expression by dendritic cells, which may contribute to the means by which this 
bacterium is able to suppress local immune response and chronically colonize the stomach of 
more than 50% of the world’s population [60].  The decreased IL-6 expressed by H. pylori 
sonicate-tolerized DCs demonstrated in this study may also contribute to an 
immunosuppressive effect caused by H. pylori that leads to its immune escape and eventually 
chronic infection.  In a recent study, it was shown that IL-6 was required to activate the 
inflammatory TH17 response in the recognition of apoptotic cells [61], so the decrease in IL-6 
production by H. pylori tolerized DCs might aid in preventing an adequate, robust adaptive 
immune response and allow the continued presence of the bacterium.  It is possible that H. 
pylori exposure, but not LPS or E. coli exposure, leads to cell processes that post-
transcriptionally modify IL-6 in tolerized DCs, however pinpointing the mechanism by which this 
occurs would require more in depth investigation (a scan of the literature did not reveal any 
research published on this subject).  
Concerning the potent anti-inflammatory cytokine IL-10, this study has revealed its 
expression as being significantly increased when BM-DCs are tolerized with LPS or sonicate 
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(Figure 5 and Figure 6). This same phenomenon is exhibited by monocytes and macrophages 
tolerized with endotoxin, and our data demonstrates that it can also occur with bacterial 
sonicate.  IL-10 has wide-ranging effects on tissue, first being recognized for its ability to 
suppress the adaptor function of T cells, monocytes, and macrophages by limiting and 
eventually terminating the inflammatory response, as well as affecting the development and 
differentiation of B cells, NK cells, cytotoxic and helper T cells, mast cells, granulocytes, 
dendritic cells, keratinocytes, and endothelial cells [62]. Notably, is has a strong influence on 
the development of regulatory T cells involved in tolerogenic immune responses [62]. Thus, 
increased IL-10 produced by tolerized DCs, as demonstrated in this study, would serve as a 
highly potent signal in terminating or limiting immune responses systemically and locally. 
Yet another interesting finding from this study is that IL-10, despite its wide-ranging 
effects leading to immunosuppression, does not appear to play a role in the development of 
tolerance in BM-DCs (Figure 8).  When we cultured tolerized BM-DCs and stimulated them in 
the presence of IL-10 neutralizing antibody, there was no identifiable change in TNF-α 
expression.  If IL-10 were playing an autocrine role in suppressing inflammatory cytokine 
expression in tolerized DCs, a significant increase in TNF-α would be expected to occur in 
tolerized cells cultured with the neutralizing antibody and challenged with a stimulus; however, 
this study indicates this is not the case.  It is possible that another anti-inflammatory cytokine, 
such as TGF-β, is at least partially responsible for the immunomodulated cytokine profile of 
tolerized dendritic cells in this study.  Another possibility is the up-regulation of intracellular 
negative regulators of inflammatory signaling, of which a large cohort have been identified [38, 
63]. The roles of negative regulators of TLR signaling, specifically, have been recognized for 
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several years in controlling the inflammatory response; if these proteins are the main source of 
pro-inflammatory cytokine regulation in BM-DCs, then it would not be particularly surprising 
that neutralizing the anti-inflammatory cytokine IL-10 resulted in little fluctuation in TNF-α as 
compared to non-IL-10 neutralized cells that had been tolerized.  In order to confirm that IL-10 
has little role in immunomodulation through autocrine action, further pro-inflammatory 
cytokines measurements should be carried out. 
Concerning intracellular negative regulators, this study investigated the role of 
interleukin 1 receptor-associated kinase (IRAK-M), a negative regulator of TLR-signaling, in the 
tolerance of BM-DCs.  IRAK-M was chosen to be investigated since this protein has been 
demonstrated to be expressed in high amounts in tolerized monocytes and macrophages, and 
even essential to the development of tolerance within these cells [10-12, 14, 29, 34, 37, 40, 64].  
IRAK-M has been shown to interact with IRAK-1 and IRAK-4 to prevent them from dissociating 
from the TLR4/MyD88 adapter complex [40].  This dissociation is necessary to continue the 
signal cascade through NF-κB, which serves as a transcriptional activator for an array of 
inflammatory cytokines [1].  It is not clear how exactly IRAK-M does this, but it is theorized to 
either participate in modulating phosphorylation or stabilizing the complex to prevent the 
dissociation [40]. When BM-DCs were tolerized with LPS, our data indicate that IRAK-M does 
indeed show increased expression (Figure 9).  This was shown by both increased IRAK-M 
transcript (qPCR) and protein expression (Western blot).  As in monocytes and macrophages, 
IRAK-M appears to have a correlation to tolerization status in BM-DCs. 
However, investigation beyond correlative participation of IRAK-M in tolerance in BM-
DCs yielded surprising results.  Given the phenotypic and functional relation of dendritic cells to 
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macrophages and monocytes, it might be hypothesized that IRAK-M would a have a similar role 
as being an important member in tolerance development; yet, data from this study seem to 
indicate quite the opposite.  IRAK-M knockout mice with a truncated and non-functional IRAK-
M protein were obtained through the generous contribution of Ted Standiford (University of 
Michigan), and bone marrow cells were taken from these and cultured to produce BM-DCs in 
an identical manner as wild type BM-DCs.  When these cells were tolerized, they not only failed 
to show a lack tolerizability but seemed to decrease the expression of TNF-α as compared to 
tolerized wild type BM-DCs (Figure 10).  Since the current understanding of IRAK-M is that its 
presence is necessary for decreased TNF-α expression in macrophages and monocytes, these 
results are exceedingly unexpected.  A few possibilities may underlie this observation; firstly, 
IRAK-M function in dendritic cells may be constitutive, that is, the protein may simply always be 
expressed at a basal level and any increased expression does not have any sort of noticeable 
effect on dendritic cells.  This assertion is supported in Figure 9, where totally untolerized and 
un-stimulated BM-DCs exhibit IRAK-M expression.  Thus, DCs would be unresponsive to 
additional IRAK-M since its concentration of maximal functionality has already been met or 
surpassed in an untolerized state. A second possibility is that IRAK-M functions to suppress the 
expression other negative regulators during tolerance in dendritic cells. This up-regulation of 
other negative regulators in the absence of IRAK-M might explain why the suppression of TNF-α 
is maintained in tolerized DCs, and indeed enhanced.  Several negative regulators may behave 
this way in dendritic cells [38], such as SOCS1, PI3K, NOD2, TOLLIP, SIGIRR, TRAILR, TRIAD3A, 
MyD88s, A20 or sTLR4, but a confirmation of this would require further analysis, such as a chip 
array, which was not conducted within the confines of the current study.  A third, though 
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unlikely, explanation would be that IRAK-M merely has an entirely different or unidentified 
functional role in the tolerance of DCs, doubtful given the close relation between dendritic cells 
and monocytes/macrophages. 
IRAK-M -/- DCs with tolerance also showed peculiar behavior with regards to IL-10.  In 
the DCs tolerized with endotoxin, the typical increase in IL-10 was observed; however, in IRAK-
M -/- DCs tolerized with either bacterial sonicate, no increase in IL-10 was seen compared to 
untolerized IRAK-M -/- cells (Figure 11).  This would seem to indicate differing roles of IRAK-M 
depending on whether the cells are interacting with and being tolerized by a single ligand 
(endotoxin) or multiple ligands (aggregate bacterial sonicate); in cells tolerized with mixed 
bacterial components, IL-10 expression could not be potentiated above levels expressed by 
non-tolerized cells without IRAK-M present.  Since IL-10 is regulated through a different 
signaling adapter as compared to TNF-α (MyD88 vs TRIF/JAK-STAT1), it would not be surprising 
that IL-10 might show a non-uniform trend depending on the tolerization component(s) as 
compared to the uniform trend displayed by TNF-α, regardless of tolerization component(s).  
The fact that IL-10 expression can be altered by the absence of a functional IRAK-M protein in 
dendritic cells is novel, chiefly since IRAK-M has only been researched in the context of MyD88-
related signaling.  Consequently, these results may indicate additional molecular sites of action 
under the influence of IRAK-M. 
 41 
 
C O N C L U S I O N  
This study has demonstrated that BM-DCs are capable of immunomodulation during 
tolerance involving E. coli-derived endotoxin and sonicate containing various stimulatory 
ligands derived from the Gram (-) bacteria Escherichia coli and Helicobacter pylori.  This 
immunomodulation is typified by suppressed expression of pro-inflammatory cytokines TNF-α, 
IL-12, with uniquely suppressed expression of IL-6 in BM-DCs tolerized with H. pylori sonicate, 
and increased expression of the anti-inflammatory cytokine IL-10.  IL-10 does not appear to 
have an autocrine immunosuppressive effect during this tolerance.  Although IRAK-M, a 
negative regulator of immune signaling, showed enhanced expression in BM-DCs tolerized with 
endotoxin, it does not appear to be necessary for tolerance as in monocytes and macrophages; 
indeed, the absence of IRAK-M enhanced tolerance with respect to TNF-α expression.  IL-10 
expression increased in endotoxin-tolerized, but not sonicate-tolerized, IRAK-M -/- BM-DCs, 




F U T U R E  D I R E C T I O N S  
o Continued cytokine analysis to better reveal cytokine modulation in IL-10 neutralization 
and IRAK-M -/- tolerization experiments 
o Characterize IRAK-M in sonicate-induced tolerance of BM-DCs 
o Isolation of H. pylori LPS, in order to characterize tolerance with E. coli LPS vs H. pylori 
LPS 
o Testing for modulation of additional negative regulators of inflammatory signaling and 
TGF-β to better ascertain the cellular processes leading to DC tolerization 
o Attempt TGF-β neutralization to observe whether it has an autocrine 
immunosuppressive effect on tolerized DCs 
o Utilize flow cytometry to assess cell maturation and surface marker expression in 
varying conditions of DC tolerance, as well as intracellular protein expression 
o Conduct experiments with tolerized DCs co-cultured with naïve T cells in order to 
observe T cell subtype skewing 
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A B B R E V I A T I O N S  
o BM-DC (DC) – bone marrow-derive dendritic cell (dendritic cell) 
o LPS – lipopolysaccharide (endotoxin) 
o TNF-α – tumor necrosis factor - alpha 
o TGF-β – transforming growth factor beta 
o IL-#p# - interleukin-# subunit # 
o IRAK-( ) – interleukin 1 receptor-associate kinase-( ) 
o NF-κB – nuclear factor kappa B 
o TLR – Toll-like receptor 
o qPCR – quantitative polymerase chain reaction 
o APC – antigen presenting cell 
o PRR – pattern recognition receptor 
o PAMP – pathogen associate molecular pattern 
o MAP kinase – mitogen-activated protein kinase 
o ET – endotoxin tolerance 
o MyD88 – myeloid differentiation factor 88 
o TRIF - TIR-domain-containing adapter-inducing interferon-β 
o IκB – inhibitor of nuclear factor kappa B kinase 
o GM-CSF – granulocyte/macrophage – colony stimulating factor 
o PBS – phosphate buffered saline 
o GAPDH – glyceraldehyde-3 phosphate dehydrogenase 
o ELISA – enzyme-linked immunosorbent assay 
o SDS-PAGE – sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
o IgG – immunoglobulin G 
o ND50 – 50% neutralizing dose 
o NK – natural killer 
o SOCS1 – suppressor of cytokine signaling 1 
o PI3K – phosphoinositol 3 kinase 
o NOD2 - nucleotide-binding oligomerization domain containing 2 
o TOLLIP – Toll interaction protein 
o SIGIRR - single immunoglobulin IL-1R-related molecule   
o MyD88s – short form of MyD88 
o sTLR4 – short form of TLR4 
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